HUMA
Humacyte IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$233.12M
P/E Ratio
—
EPS
$-0.63
Beta
2.31
52W High
$2.93
52W Low
$0.55
50-Day MA
$0.83
200-Day MA
$1.24
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
35.84
PEG Ratio
—
About Humacyte Inc
Humacyte Inc (HUMA) is an innovative biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs) aimed at addressing critical clinical demands in vascular reconstruction and chronic disease management. By offering off-the-shelf solutions, Humacyte enhances patient outcomes while aiming to reduce overall healthcare expenditures. Leveraging its cutting-edge technology platform, the company is well-positioned to lead advancements in transplantation and tissue engineering, establishing itself as a key player in the rapidly evolving medical therapies sector.
Fundamentals
| Revenue (TTM) | $2.02M |
| Gross Profit (TTM) | $-81.72M |
| EBITDA | $-105.19M |
| Operating Margin | -5704.00% |
| Return on Equity | -409.50% |
| Return on Assets | -51.50% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.02 |
| Price-to-Book | 19.86 |
| Price-to-Sales (TTM) | 115.63 |
| EV/Revenue | 123.15 |
| EV/EBITDA | 4.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -4.30% |
| Shares Outstanding | $222.02M |
| Float | $190.79M |
| % Insiders | 9.12% |
| % Institutions | 26.96% |
Historical Volatility
HV 10-Day
176.32%
HV 20-Day
141.32%
HV 30-Day
122.15%
HV 60-Day
125.06%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($5.00 target)
2
Strong Buy4
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026